Results 11 to 20 of about 8,864 (209)

Neo-adjuvant systemic radiation therapy for inoperable hepatic hilum neuroendocrine tumor with 177Lu- DOTATATE: successful final surgical resection [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology
The role of neoadjuvant therapy in neuroendocrine tumors (NET) remains an area requiring further advanced clinical exploration. 177Lu-DOTATATE has demonstrated significant therapeutic efficacy in managing metastatic NET, with reports of notable tumor ...
Ali Moradi, Fatemeh Sharifian, Saeed Farzanefar, Mohammad Ghasri, Mehrshad Abbasi   +4 more
doaj   +2 more sources

Searching for Synergy : Radiosensitization of 177Lu-DOTATATE

, 2022
Cancers presents a major health challenge, and there is a pressing need to develop new therapeutic strategies. Surgery, chemotherapy and radiation are the most commonly used treatments for cancer today. Radiation can be given as targeted radionuclide therapy (TRT), i.e., systemic administration of a radiolabeled cancer-targeting molecule.
Lundsten, Sara
core   +4 more sources

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

EJNMMI Research, 2019
Background The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking.
Madhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal   +2 more
doaj   +2 more sources

Potentially fatal crisis after 177Lu-DOTATATE therapy for paraganglioma: a case report with review of literature [PDF]

Endocrine Journal
Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with 177Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor ...
Aoki Tobimatsu, Kosuke Mukai, Yoshinari Obata, Kayako Isohashi, Kazuyuki Miyashita, Atsunori Fukuhara, Hiroki Kato, Iichiro Shimomura   +7 more
doaj   +2 more sources

Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy [PDF]

, 2019
Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging,
O'Neill, Edward, Kersemans, Veerle, Allen, P Danny, Terry, Samantha Yorna Armstrong, Baguna Torres, Julia, Mosley, Michael, Smart, Sean, Quan Lee, Boon, Falzone, Nadia, Vallis, Katherine, Konijnenberg, Mark, de Jong, Marion, Nonnekens, Julie, Cornelissen, Bart   +13 more
core   +6 more sources

CTNI-80. 177LU-DOTATATE IN PATIENTS WITH RECURRENT MENINGIOMA [PDF]

Neuro-Oncology
Abstract BACKGROUND There are no effective medical therapies for patients with meningioma who progress after surgical and radiotherapeutic interventions. Somatostatin receptor type 2 (SSTR2) represents a promising treatment target in meningiomas.
Nasrollahi, Elham, Drappatz, Jan
openaire   +3 more sources

Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE [PDF]

Endocrine Oncology
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity.
Eleonora Pelle, Taymeyah Al-Toubah, Ghassan El-Haddad, Brian Morse, Bhavana Konda, Vineeth Sukrithan, Jonathan Strosberg   +6 more
doaj   +2 more sources

Radiation exposure to families of patients following administration of 177Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours [PDF]

EJNMMI Physics
Background The administration of 177Lu-DOTATATE peptide receptor radionuclide therapy to patients for the treatment of well-differentiated, metastatic neuroendocrine tumours poses an external radiation hazard due to gamma emissions of lutetium-177 ...
D. Levart, S. Wicks, N. Heraghty, E. Kalogianni, N. Mulholland   +4 more
doaj   +2 more sources

Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data [PDF]

J Nucl Med
Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to confirm sufficient tumor SSTR expression, but it also has potential to be used to personalize treatment by predicting ...
Rahmim, Arman, Wang, Chang, Akhavanallaf, Azadeh, Wong, Ka Kit, Kurkowska, Sara, Hope, Thomas A., Peterson, Avery B., Blakkisrud, Johan, Sjögreen Gleisner, Katarina, Stokke, Caroline, Yadav, Surekha, Uribe, Carlos, Beauregard, Jean Mathieu, Dewaraja, Yuni K., Lu, Zhonglin   +14 more
core   +2 more sources

Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

EJNMMI Physics, 2019
Background 177Lu-DOTATATE peptide receptor radionuclide therapy is administered to patients on an inpatient and outpatient basis for the treatment of well-differentiated, metastatic neuroendocrine tumours. Following administration, these patients present
D. Levart, E. Kalogianni, B. Corcoran, N. Mulholland, G. Vivian   +4 more
doaj   +2 more sources